"The U.S. Food and Drug Administration today approved Brisdelle (paroxetine)to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mes"...
Duavee Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Duavee (conjugated estrogens/bazedoxifene) contains a form of the female hormone, estrogen, along with an estrogen agonist/antagonist used to treat moderate to severe vasomotor symptoms associated with menopause and to prevent postmenopausal osteoporosis in women who still have a uterus. Common side effects of Duavee include muscle spasms, nausea, vomiting, diarrhea, indigestion, upper abdominal pain, stomach pain or discomfort, throat or sinus pain, dizziness, and neck pain.
The recommended dosage is one Duavee tablet daily. Duavee may interact with St. John's Wort, phenobarbital, carbamazepine, rifampin, antibiotics, azole antifungals, ritonavir, grapefruit juice, and phenytoin. Tell your doctor all medications and supplements you use. Duavee must not be used in women who are or may become pregnant. It is unknown if this drug is passes into breast milk. Estrogens can decrease the quantity and quality of the milk. Duavee is not recommended for use while breastfeeding.
Our Duavee (conjugated estrogens/bazedoxifene) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Duavee FDA Prescribing Information: Side Effects
The following adverse reactions are discussed in greater detail in other sections of the label:
- Cardiovascular Disorders [see WARNINGS AND PRECAUTIONS]
- Malignant Neoplasms [see WARNINGS AND PRECAUTIONS]
- Gallbladder Disease [see WARNINGS AND PRECAUTIONS]
- Hypertriglyceridemia [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of conjugated estrogens/bazedoxifene was evaluated in four Phase 3 clinical trials ranging from 12 weeks to 24 months in duration and enrolling 6,210 postmenopausal women age 40 to 75 years (mean age 55 years). A total of 1,224 patients were treated with DUAVEE and 1,069 patients received placebo. Women enrolled in Studies 1 and 2 received calcium (600-1200 mg) and vitamin D (200-400 IU) daily, while women in Studies 3 and 4 received no calcium and vitamin D supplementation as part of the protocol.
The incidence of all-cause mortality was 0.0% in the DUAVEE group and 0.2% in the placebo group. The incidence of serious adverse reactions was 3.5% in the DUAVEE group and 4.8% in the placebo group. The percentage of patients who withdrew from treatment due to adverse reactions was 7.5% in the DUAVEE group and 10.0% in the placebo group. The most common adverse reactions leading to discontinuation were hot flush, abdominal pain upper, and nausea.
The most commonly observed adverse reactions (incidence ≥ 5%) more frequently reported in women treated with DUAVEE than placebo are presented in Table 1.
Table 1: Adverse Reactions (Incidence ≥ 5%) More
Common in the DUAVEE Treatment Group in Placebo-controlled Trials
|Nausea||100 (8)||58 (5)|
|Dyspepsia||84 (7)||59 (6)|
|Abdominal pain upper||81(7)||58 (5)|
|Musculoskeletal and connective tissue disorders|
|Muscle spasms||110 (9)||63 (6)|
|Neck pain||62 (5)||46 (4)|
|Nervous system disorders|
|Dizziness||65 (5)||37 (3)|
|Respiratory, thoracic, and mediastinal disorders|
|Oropharyngeal pain||80 (7)||61(6)|
In the clinical studies with DUAVEE, the reporting rates for venous thromboembolism (deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis) were low in all treatment groups. Adverse reactions of venous thromboembolism were reported in 0.0% of patients treated with DUAVEE and 0.1% of patients treated with placebo. Due to the low rate of events in both groups, it is not possible to conclude that the risk of venous thromboembolism with DUAVEE is different from that seen with other estrogen therapies [see WARNINGS AND PRECAUTIONS].
Read the entire FDA prescribing information for Duavee (Conjugated Estrogens and Bazedoxifene Tablets)
Additional Duavee Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.